All articles tagged with #mhra
Originally Published 8 days ago — by London Evening Standard
Emergency hospital cases linked to weight-loss injections like Ozempic, Wegovy, and Mounjaro have surged by 60% in 2025, with three deaths reported, raising concerns over safety and regulation of the booming market.
Originally Published 3 months ago — by GOV.UK
The MHRA has confirmed that taking paracetamol during pregnancy is safe and does not cause autism in children, emphasizing that it remains the recommended pain relief when used as directed and that ongoing monitoring and scientific assessment support this guidance.
Originally Published 6 months ago — by BBC
A study has been launched to investigate serious side effects, including pancreatitis, linked to weight loss drugs like Mounjaro, Ozempic, and Wegovy, after reports of hospitalizations and deaths. The research aims to identify genetic risk factors to improve safety and reduce adverse reactions, with data collection through the MHRA's Yellow Card scheme and saliva samples from affected patients.
Originally Published 2 years ago — by Daily Mail
The Medicines and Healthcare products Regulatory Agency (MHRA) has instructed doctors to limit the prescription of fluoroquinolone antibiotics due to safety concerns, including a link to suicidal thoughts. These antibiotics should only be prescribed when no other drug is deemed appropriate, and patients are advised to discontinue use at the first signs of serious adverse reactions. The crackdown follows reports of irreversible harm such as tendon rupture, nerve, joint and muscle pain, fatigue, insomnia, and gut problems associated with fluoroquinolones. Patients are urged to carefully read the patient information leaflet and seek immediate medical advice if they experience specific side effects.
Originally Published 2 years ago — by GOV.UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new restrictions for fluoroquinolone antibiotics, stating that they should only be prescribed when other antibiotics are inappropriate due to resistance, contraindications, failure of first-line antibiotics, or side effects. This comes after reports of long-lasting adverse reactions from patients, prompting the MHRA to prioritize patient safety and advise careful monitoring for potential side effects, including those related to tendons, muscles, joints, nerves, and mental health. Healthcare professionals are reminded to be vigilant about the risk of suicidal thoughts and behaviors associated with fluoroquinolone antibiotics, and patients are encouraged to report any suspected adverse reactions via the Yellow Card scheme.
Originally Published 2 years ago — by BBC.com
A man in his 30s has been arrested in East Yorkshire on suspicion of illegally selling "skinny jabs" online. Police raided a house near Hull and seized vials believed to contain semaglutide, the active ingredient in the weight loss drug Ozempic. The Medicines and Healthcare Products Regulatory Agency (MHRA) and Humberside Police conducted the operation, targeting the black market supply of semaglutide. The MHRA has launched a crackdown on black market sellers due to increased demand for weight loss jabs and other products. Taking semaglutide incorrectly can have serious side effects, and unregulated versions may be toxic.
Originally Published 2 years ago — by Daily Mail
Health officials have issued an urgent warning to parents, advising them not to use kits designed to collect breast milk for feeding babies due to a serious risk of choking. The SteriFeed Colostrum Collector, a syringe-style device used to collect colostrum, has been found to have its cap lodged in the throats of six newborns when used for feeding without removing the stopper. While no fatalities have occurred, one infant required emergency surgery. The Medicines and Healthcare products Regulatory Agency (MHRA) has urged users to contact their healthcare provider for advice on safe collection and feeding methods. The manufacturer will be changing the device's design to minimize the choking risk, but this will take six months to implement.
Originally Published 2 years ago — by Reuters
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK is reviewing the safety of a class of drugs known as GLP-1 receptor agonists, which includes Novo Nordisk's diabetes medicine Ozempic and weight-loss treatment Saxenda, after some patients reported suicidal or self-harming thoughts. The review follows similar action taken by the European Union. Novo Nordisk has confirmed receiving a request from the MHRA and stated that it will respond within the requested timelines. Other GLP-1 drugs from AstraZeneca, Sanofi, and Eli Lilly are also included in the review. The MHRA's review will consider safety data, including adverse drug reactions reported by patients and clinicians.